Prognosis
Moderna Sales Were $6.7 Billion Last Year on Rising Vaccine Share
- Vaccine-maker still expects revenue to fall sharply this year
- Company says it won’t return to sales growth until 2025
Does of the Moderna Covid-19 vaccine.
Photographer: Eugene Hoshiko/AP PhotoThis article is for subscribers only.
Moderna Inc.’s sales for 2023 modestly beat analyst estimates as it eked out a bigger US market share for Covid shots, though the biotech giant reiterated a downbeat outlook for the year ahead.
The company reported $6.7 billion in unaudited Covid vaccine sales ahead of its presentation Monday at the JPMorgan Healthcare Conference in San Francisco. That includes includes $6.1 billion from its coronavirus shots — which have a 48% market share in the US — and $600 million in deferred revenue related its work with GAVI, a global health initiative to boost immunization.